Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Not yet recruiting 2Unknown 1Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 2Sarcoma 1NET 1Head & Neck 1Endocrine 1

Conditions

Pancreatic Neoplasms 9Neuroendocrine Tumors 8Small Cell Lung Carcinoma 7Biliary Tract Neoplasms 5Stomach Neoplasms 4Sarcoma 4Cholangiocarcinoma 4Ovarian Neoplasms 3Osteosarcoma 3Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Neoplasm Metastasis 2Colorectal Neoplasms 2Carcinoma, Neuroendocrine 2Carcinoma, Hepatocellular 2Advanced Colorectal Cancer 2Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Solid Tumor 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Refractory Metastatic Digestive System Carcinoma 1Pulmonary Neuroendocrine Tumor 1Pancreatic cancer, adult 1Pancreatic Cancer Metastatic 1Neuroectodermal Tumors, Primitive 1NSCLC 1Lymphoma 1Locally Advanced Pancreatic Cancer 1

Interventions

Oxaliplatin 290Capecitabine 206Fluorouracil 181Cisplatin 168Docetaxel 138S 1 (combination) 132Paclitaxel 121Leucovorin 116Irinotecan 106pembrolizumab 103Trastuzumab 72apatinib 56Nivolumab 56sintilimab 45Drug Therapy 43Surgical Procedures, Operative 37Radiotherapy 37Bevacizumab 37Ramucirumab 34titanium silicide 31Hyperthermic Intraperitoneal Chemotherapy 30Epirubicin 30Carboplatin 30tislelizumab 28Cyclophosphamide 27XELOX 24Tegafur 23Folfox protocol 22Albumin-Bound Paclitaxel 22camrelizumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Stomach Neoplasms × surufatinib × Clear all
NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
87 enrolled 29 charts
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT06531291 2024-07-31

Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation

RenJi Hospital

Phase 2 Not yet recruiting
80 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT06447636 2024-06-07

Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma

Fudan University

Phase 2 Not yet recruiting
20 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05527821 2022-09-06

Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Unknown
36 enrolled
GastrointestinalThoracic

Stomach Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡